glp-1 depression Reassuring' findings suggest receptor agonists do not increase suicide risk GLP-1 Agonists In Obesity

Description

The study found increased risk in both patients with type 2 diabetes and patients using semaglutide for overweight or obesity, but the authors noted that the study was observational and could not prove that semaglutide directly caused NAION

Trends in the GLP-1RA Market The study on the antiobesity medications shows an exponential growth in recent years

Whether trace exposure through breast milk could affect infant GIP signaling is unknown but considered unlikely given the undetectable milk levels

Among survey respondents, 76% provide GLP-1 drug coverage for diabetes, 27% provide coverage for weight loss, and 13% are considering covering for weight loss